Hyperion gets rights to Ravicti, and perhaps more, from Ucyclyd
Privately-held US firm Hyperion Therapeutics has acquired worldwide rights to the investigational drug Ravicti (glycerol phenylbutyrate) from Ucyclyd Pharma, a wholly-owned subsidiary of Medicis Pharmaceutical (NYSE: MRX). Terms of the deal were not disclosed.
In connection with the accord, Hyperion also entered into an amended and restated collaboration with Ucyclyd to retain an option to acquire, in the first half of 2013 for a pre-negotiated price, worldwide rights for Buphenyl (sodium phenylbutyrate) and, subject to certain conditions, Ammonul (sodium phenylacetate and sodium benzoate) Injection.
NDA for urea cycle disorders under review by FDA
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze